Publicacións nas que colabora con Vicente Bertomeu González (71)

2024

  1. Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty

    Angiology, Vol. 75, Núm. 2, pp. 175-181

  2. Classification tree obtained by artificial intelligence for the prediction of heart failure after acute coronary syndromes

    Medicina Clinica, Vol. 163, Núm. 4, pp. 167-174

  3. Lifestyle Habits and Risk of Cardiovascular Mortality in Menopausal Women with Cardiovascular Risk Factors: A Retrospective Cohort Study

    Journal of Cardiovascular Development and Disease, Vol. 11, Núm. 9

  4. Predictive validity of the risk SCORE model in a Mediterranean population with arterial hypertension

    Medicina Clinica, Vol. 162, Núm. 3, pp. 112-117

2023

  1. Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 2, pp. 157-164

  2. Risk factors for major adverse cardiovascular events in postmenopausal women: UK Biobank prospective cohort study

    Atherosclerosis, Vol. 386

  3. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 4, pp. 165-177

2022

  1. Anticoagulation in patients with valvular heart disease, beyond the rhythm

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 231-233

  2. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 4

  3. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

    European Journal of Internal Medicine, Vol. 99, pp. 45-56

  4. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

    BMC Medicine, Vol. 20, Núm. 1

  5. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 5, pp. 721-728

  6. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 7

  7. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 6

  8. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  9. Myocarditis after RNA-based vaccines for coronavirus.

    International Journal of Cardiology, Vol. 353, pp. 131-134

2021

  1. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169

  2. Direct oral anticoagulants versus warfarin in octogenarians with nonvalvular atrial fibrillation: A systematic review and meta‐analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 22

  3. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

    BMC Medicine, Vol. 19, Núm. 1

  4. Managing NSTEMI in older patients

    The Lancet